1.52
+0.04(+2.70%)
Currency In USD
| Previous Close | 1.48 |
| Open | 1.5 |
| Day High | 1.53 |
| Day Low | 1.46 |
| 52-Week High | 8.4 |
| 52-Week Low | 1.23 |
| Volume | 314,799 |
| Average Volume | 875,332 |
| Market Cap | 56.82M |
| PE | -0.64 |
| EPS | -2.36 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 2.67 |
| Change | 0.04 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $147.43 as of April 19, 2025 at a share price of $1.52. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $147.43 as of April 19, 2025 at a share price of $1.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 17, 2025 8:05 PM GMT
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vi
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
GlobeNewswire Inc.
Mar 13, 2025 10:19 AM GMT
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compac
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 11, 2025 1:55 PM GMT
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that
Data not available